Clinical Trial

Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS

Name: Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS — clinical trial record (NCT06925555)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 2

View on ClinicalTrials.gov →

Summary

Evaluation of the Safety and Efficacy of Brentuximab Vedotin Combined With R-CHP in Newly Diagnosed EBV+ DLBCL-NOS.

Protocol Amendment History 1 amendment

This ClinicalTrials.gov record has been amended once since 2025-04-10.

Trial Details

NCT Number	NCT06925555
Lead Sponsor	The First Affiliated Hospital with Nanjing Medical University
Conditions	EBV-Positive Diffuse Large B-Cell Lymphoma, Nos, Brentuximab Vedotin
Enrollment	25 participants
Start Date	2025-09
Primary Completion	2028-12-30 (estimated)
Study Completion	2028-12-30 (estimated)
Updated on ClinicalTrials.gov	2025-09-30